{"name":"Vasomune Therapeutics, Inc.","slug":"vasomune-therapeutics-inc","ticker":"","exchange":"","domain":"vasomune.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AV-001","genericName":"AV-001","slug":"av-001","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"AV-001","genericName":"AV-001","slug":"av-001","phase":"phase_2","mechanism":"AV-001 is a small molecule that targets the PI3K pathway to modulate immune responses.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic melanoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOWTJJamtvQjdYQ19ZVlVpT1dJR01lUXpJS2plZFctT0dET2U1QlgxbHdFRWVrdDNydGNPMUlTVk94ZXQ0MlR0MnhRYWhKbHo1TkJNSHhTMGE5VUtBTGc4NUcyUWlOd2dLRkM1QXlmOUUzNW1wd1Y2Y0VBU0JNNnZkdG5lTF9zb0ZkeEFhc2lqU0Q2dGk4eENqXzhDajY?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Future Perspectives: Key Trends Shaping the Acute Lung Injury Market Until 2030 - openPR.com","headline":"Future Perspectives: Key Trends Shaping the Acute Lung Injury Market Until 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxPMmdYMjJvSWJiZkVZcGxCVGxqUnRvWUYtNnZGb3BkVmNHM0ZxelExSENoYWxnQzZEN1BuWHJTTmVrT2tIQ1NFdGhFOU5QM0FTdi0xRldJc2p0VHcyMDJQelIwdlhtNERfdzQtTW00Rmg1dlBFdmNtREp2aUJlRl9xXzNfUllTZ2xDUEM1WFJUNWFzX0xmaUdkTlpISjZIclF2NjRvXzItdXBtQnFFVXhXdXRQVDVGdXdBc1JXNmFRUDU4TlNRVFZBYVY2eFNic0ZHUXBMR0dTNXh4Smdrbkx2VkdPNXpXZTZRRkE4QTBXbFlkSVNQenZ1d2Q1V1RvVHdsMTQ5LXRLLUE1RkFMeUtueUYxMEF6QTQ?oc=5","date":"2026-03-24","type":"trial","source":"Business Wire","summary":"First Patient Dosed in New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients - Business Wire","headline":"First Patient Dosed in New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialys","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxONGFpRVkwTTNZMUlaRzFxZWFVSWdhbHdOZGRTTDdVbWhueFNuRWF0X3NEa3ZLc0hzRzBwbHQ4eE1wVWFrMFlxV2NBZUlMeDJkRGJlVXkwWGp2Q2YzUFRpVUk2cXlaMjBhbkpVN2JOcjhWc3lSLWhnRHpBNE5STERPSUpJWVdMdGJ5QUpSTzgtX3NYZjMxeHpLRklvRQ?oc=5","date":"2026-03-19","type":"pipeline","source":"openPR.com","summary":"Acute Respiratory Distress Syndrome Pipeline 2026: Therapies - openPR.com","headline":"Acute Respiratory Distress Syndrome Pipeline 2026: Therapies","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-04","type":"regulatory","source":"Business Wire","summary":"Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients ","headline":"Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application Fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxQSDRBUkxJUkFyRVF4N3FnWURTamszRGtVQjlLUlpVdkJ4VnktLWxMVFhVOFFVdWt0Rzk3QXhBN2cwMUJ5b2tRa1lfWWotNENzNHh6blBGQ3EyUVdWMWtycjExTi1Gdjk1SjM4SnRSRGNzZGkxcHEwcXBLbk9ZTTR3RzhpSlpzOVRBcjFtUElQY3BoY1RaQlNMRE9DS1BreFVsbjdQazJyb2dRSjJtc1VUVXR2akR2WU1HTlZ4UTJRVGxKTUNNb3FDRHB4TW5TTnZlanhWUnpaYkpudG5GTFgyTnJhQ3pOQjJwdkFtekV4WGF4ejNseFdpY1dJRjlFM1kzU2xHNl81T3Z2dkZT?oc=5","date":"2025-11-25","type":"pipeline","source":"Business Wire","summary":"Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications - Business Wire","headline":"Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indica","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxOREJjc2JPb21MRTk0MXVWZm5CMHJteURXY3QxblpHLXRMRnVTWEY0QVpjbFZneTk1bFhmaXZwbXdmdGNpMl9EYUpMVlg5WXF5cS1LandvN1ctVzFnWEF2dEh2N1I3S0w0azl5cWxLRndXZHBzZkNzdmRvWFI0VWJJUklvVlRVeVI4X0NlN1lFcTFPZkRhNnpua3FxZmVnYVBycnVGNjZqOHZheXdrbFlLc3Y5N19RMmplbC1qTkg0TEw2RjZRS1A1RjRKemh0Y3EwcDhIa0hOQ1VRVUVCVk1tSGJ4RFZadlF1NjAyT0xsc3RKTkUySmZmRFlmU3lfTU5MVWlzb1lfZXdNWk1vT25BSUxKTC1tc2pPTnM3MUpfYjZza0JoRDlJ?oc=5","date":"2025-09-03","type":"trial","source":"Business Wire","summary":"Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients - Business Wire","headline":"Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxPYXBQbDk4RUdjNDh2OFBDTzJGWHJlMVUxaXYtLXU2T2pBOHNXYzlmTFdyUnlOODFhOXdpaGZKQmxRYjBSeEk1b0NwcUFRdjV4bFU3dFBBSWpuMkN4VU1XWTAyV1F5Vkl0MlktcEVIdWR2aGRKbmRkbWxwTGs0YmFxQXkyOFNjcHpRcGRlUmFqY0stZ0xzU0oza0RWTmNHZldKQ1Z4d2ZrbVJCZE54VHAtNE5ZQlNCNko0WVgxMHJKay1fZHFFajBZWHJNeUYxTDFyLTlQSFJOQk9kbWZtMmtRbEk2elpvZ2xVcGlZMlBBSHl3SGNjNXdneEt6MFVBQ3Jkem5fMFZnR3RNejIzYl9CVDhQeG9zcGd6MENmWC1xaEdfZGtySVQyNlI5VHNldHM?oc=5","date":"2024-12-03","type":"trial","source":"Business Wire","summary":"Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive IDSMB Recommendation to move to the High-Dose Cohort for AV001-004 Phase 2a Study - Business Wire","headline":"Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive IDSMB Recommendation to move to the High-Dose Cohort","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPWTVPSFRKaEl4MGI2bU8tOEktbmFHSTlzaFNkUlEzTFBmSFdNWkp5aWFaMVNqTkw0NkFWNHh3V2FibV9GX0N5UUxxblRraTVieDF1WDAtdEhnY2Y5cDlIYlloQ016TC16VG9WV3VoaVNlOWtGakRTOHZrOEQ0TVlnY2RodjBjM0l5QlIxaFFwd3g2QzdpX2lZaVRXNjNwWDhrLVJ5Q3didGVIa1ZEMG4wTjlBT1hVLUJN?oc=5","date":"2024-05-28","type":"regulatory","source":"Pharmaceutical Technology","summary":"Vasomune wins FDA fast track designation for lung condition treatment - Pharmaceutical Technology","headline":"Vasomune wins FDA fast track designation for lung condition treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1vbXlNRTc1UmJJcmdialNITHlGcWM3anNvMGRqQlF0bGdWN3RmTWJTaVFtNnNHRzN1d3FFN1Y4WFZ5V2Jzd3FCcEJVTXBzUWpPRnBZa253ZEl3R2pMYktreDVIUTRxczF1bk83ZTJIXzV6UQ?oc=5","date":"2021-01-07","type":"pipeline","source":"Straits Research","summary":"Pneumonia Therapeutics Market Size, Share & Growth Report by 2034 - Straits Research","headline":"Pneumonia Therapeutics Market Size, Share & Growth Report by 2034","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}